FIND Collaborates with SpeeDx and QuantuMDx
SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. The collaborative project will assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). SpeeDx will use their proprietary Plex PCR® technology to develop multiplex tests for common STIs, including gonorrhoea and Mycoplasma genitalium (Mgen), to be run on the QuantuMDx Q-POCTM POC device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005350/en/
SpeeDx and QuantuMDx collaborate to assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). (Photo: Business Wire)
“We are excited by this collaboration with QuantuMDx and the potential to expand access to high quality testing options to the areas of the world that really need it,” said Dr. Elisa Mokany, SpeeDx Founder and Chief Technology Officer. “Patients around the globe are already benefiting from the clinically relevant information provided by SpeeDx tests, but we are cognisant that the current platforms and processes in use to run these tests do not readily translate to all regions of the world.”
The QuantuMDx Q-POCTM is a battery-operated, microfluidics based, sample-to-answer system for low-cost molecular testing using rapid PCR followed by microarray detection.
“QuantuMDx is always looking to expand the portfolio of diagnostic tests available on the Q-POCTM platform, and this collaboration with SpeeDx is an obvious choice given the proven compatibility of their robust chemistry across a range of platform technologies” said Jonathan O’Halloran, Chief Scientific Officer at QuantuMDx Group. “We have a common goal to enhance the standard of healthcare around the globe, this partnership will accelerate our efforts and combine our lab-standard point of care device with SpeeDx world-class test technology.”
SpeeDx has commercialised a range of tests, principally for sexually transmitted infections, that are in use across Europe, Australia and New Zealand. The flagship Resistance Plus® tests for Mgen and gonorrhoea that include markers for antibiotic resistance/susceptibility have shaped patient management guidelines around the world, providing Resistance Guided Therapy options to clinicians and enabling improved care for patients while fostering antimicrobial stewardship. Resistance Plus® GC recently received FDA Breakthrough designation to accelerate the process towards clearance for use in the U.S., and clinical trials for Resistance Plus® MG are nearing completion with expected U.S. launch early 2020.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com
About QuantuMDx Group
QuantuMDx Group is a multinational company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. The company’s flagship device, Q-POC™, is a next generation DNA analyser which delivers the full power of a molecular diagnostics lab in an affordable, simple-to-use, portable, desktop system. Q-POC™ offers true sample collection-to-answer analysis in minutes, in decentralized settings. Headquartered in the UK, QuantuMDx has operations and strategic partnerships in the United States, Asia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com: https://quantumdx.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20191107005350/en/
Contact information
SpeeDx
Europe, Australia, New Zealand
Madeline O’Donoghue
madelineo@speedx.com.au
+61 2 9209 4170
United States
Rick Roose
roi.roose@gmail.com
+1 415 202 4445
QuantuMDx
Debra Daglish
Debra.daglish@quantumdx.com
+ 44 870 803 1234
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Webcast Fireside Chat at Stifel Virtual Cross Sector Insight Conference June 82.6.2020 22:15:00 CEST | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced that the Company’s management will be participating in a fireside chat at the Stifel Virtual Cross Sector Insight Conference on Monday, June 8, 2020 at 4:00 PM ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005897/en/Contact information Micha
ZOOM International to Begin Doing Business As Elevēo2.6.2020 16:00:00 CEST | Press release
ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/ For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry. Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and in
Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board2.6.2020 16:00:00 CEST | Press release
DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes. Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts fro
Andersen Global Expands Presence in Qatar2.6.2020 15:30:00 CEST | Press release
Andersen Global announced its collaboration with Doha-based tax firm MS Partner, adding depth to the organization’s presence in Qatar and expanding its global platform. MS Partner was founded in 2018 and includes two Partners and more than 10 professionals that specialize in providing tax services to a variety of international clients including individuals and companies – both private and public. MS Partner’s Chairman His Excellency Shaikh Sultan Bin Jassim Bin Mohammed Al Thani is a prominent business leader in the State of Qatar. “We value our clients and people, and maintain the highest of professional standards,” said Office Managing Director Manikandan Rajan. “We’ve watched Andersen Global grow regionally as well as globally, and the organization has set the standard for providing clients with best-in-class service in an independent and seamless manner. We look forward to working closely with our fellow collaborating firm in Doha, Al-Khalifa Law, as well as all the collaborating f
Pegasus Development AG: Pegasus Present Its New Brand Pegastril - Nuevo2.6.2020 15:06:00 CEST | Press release
The coronavirus pandemic harbours the potential for enormous growth in specific industries. To that end, however, it's important to identify which markets will be dominant in the future. One of the key growth sectors is the production and distribution of disinfectants and associated technologies. Regardless of whether a cure for, or vaccine against, COVID-19 is developed, protection against viruses and bacteria has become incredibly important across the globe and will continue to be a concern going forward. This was one of the reasons why Pegasus Development AG decided to partner with the British disinfectant manufacturer Nuevo. One of the decisive factors choosing Nuevo was its highly competitive product, which is free from alcohol, animal products, perfume, essential oils or dyes. Furthermore, the product has already been tested according to the highest stipulations of the European standard EN 1276, is manufactured according to the latest regulations of the European Biocides Directiv
PVH Corp. Announces Leadership Update at Tommy Hilfiger and PVH Europe2.6.2020 15:00:00 CEST | Press release
PVH Corp. (NYSE:PVH), owner of a portfolio of iconic brands including TOMMY HILFIGER and CALVIN KLEIN, announced today that Daniel Grieder is stepping down from his role of Chief Executive Officer, Tommy Hilfiger Global & PVH Europe after 23 years in various management roles within the organization, and will be leaving the company to pursue other interests. Martijn Hagman will succeed Grieder and become the new Chief Executive Officer, Tommy Hilfiger Global & PVH Europe, effective June 2, 2020. Hagman is currently Chief Operating Officer, Tommy Hilfiger Global & PVH Europe and Chief Financial Officer, Tommy Hilfiger Global, overseeing operations, finance, digital business transformation, technology, business development and the Tommy Hilfiger global sustainability program. He is a 12-year veteran of the Tommy Hilfiger leadership team and has been instrumental in Tommy Hilfiger’s impressive global expansion and the strategy that has led to PVH Europe’s consistent year-over-year growth.